Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
1. ANGPTL4 inhibition decreased triglyceride and remnant cholesterol levels by over 50%. 2. MAR001 was well-tolerated with no significant treatment-related ...
Tag: hypertriglyceridemia
#VisualAbstract: Plozasiran Reduces Triglyceride Levels and Pancreatitis Risk for Persistent Chylomicronemia
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Olezarsen effectively decreases triglyceride levels
1. In this randomized controlled trial, in patients with hypertriglyceridemia and elevated cardiovascular risk or severe hypertriglyceridemia, olezarsen had reduced ...
#VisualAbstract: Plozasiran reduces serum triglyceride levels in patients with severe hypertriglyceridemia
Click here to read this study in JAMA Cardiology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Pegozafermin associated with improved outcomes in nonalcoholic steatohepatitis
1. In this randomized controlled trial, treatment with pegozafermin improved fibrosis in patients with nonalcoholic steatohepatitis (NASH). 2. Treatment with ...
Pemafibrate does not lower cardiovascular risk in individuals with hypertriglyceridemia
1. In patients with type 2 diabetes and hypertriglyceridemia, pemafibrate did not alter the incidence of cardiovascular events compared to placebo. ...
#VisualAbstract: Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
1. Triglyceride levels in familial chylomicronemia patients were notably reduced when treated with the apolipoprotein C-III antisense mediated inhibitor volanesorsen ...
The APPROACH trial: volanesorsen lowers triglyceride levels in patients with familial chylomicronemia
1. Triglyceride levels in familial chylomicronemia patients were notably reduced when treated with the apolipoprotein C-III antisense mediated inhibitor volanesorsen ...
#VisualAbstract: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
1. After a median follow-up of 4.9 years, patients with elevated triglyceride levels despite statin use treated with icosapent ethyl ...
The REDUCE-IT trial: Icosapent ethyl reduces ischemic event risk in patients with hypertriglyceridemia despite statin use
1. After a median follow-up of 4.9 years, patients with elevated triglyceride levels despite statin use treated with icosapent ethyl ...
